Isis Clinical Research Austin, TX - 78731

Isis Clinical Research is categorized under Physicians Offices in Austin, TX and active since 2010.

Isis Clinical Research was established in 2010, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Physicians Offices business, which does work in the B2C market, and is classified as a Physicians Offices, under code number 6211110 by the NAICS.

If you are seeking more information, feel free to contact Van Bavel, Owner at the company’s single location by writing to 6836 Austin Center Boulevard # 180, Austin, Texas TX 78731 or by phoning (512) 349-0703. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Isis Clinical Research
Contact Person: Van Bavel, Owner
Address: 6836 Austin Center Boulevard # 180, Austin, Texas 78731
Phone Number: (512) 349-0703
Website Address: isisclinicalresearch.com
Annual Revenue (USD): $500.000 to $999.999
Founded: 2010
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Physicians Offices
SIC Code: 8011
NAICS Code: 6211110
Share This Business:

Isis Clinical Research was started in 2010 to provide professional Physicians Offices under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.

Feel free to contact Van Bavel, Owner for inquiries that concern Isis Clinical Research by calling the company number (512) 349-0703, as your correspondence is most welcome. Additionally, the physical location of the single location of Isis Clinical Research can be found at the coordinates 30.350973,-97.751119 as well as the street address 6836 Austin Center Boulevard # 180 in Austin, Texas 78731.

For its online presence, you may visit Isis Clinical Research’s website at isisclinicalresearch.com and engage with its social media outlets through on Twitter and on Facebook.